December 29, 2014 12:45 AM ET

Pharmaceuticals

Company Overview of TRACON Pharmaceuticals, Inc.

Company Overview

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, develops, licenses, and commercializes targeted therapies for cancer and age-related macular degeneration. Its products include TRC105, a human chimeric monoclonal antibody to CD105 that addresses multiple solid tumor types, including breast, kidney, prostate, ovarian, lung, liver, and bladder cancer; and TRC102, a small molecule inhibitor of base-excision repair, which is intended to reverse resistance to alkylator and antimetabolite chemotherapy, including agents used in the treatment of malignant melanoma, malignant glioma, and lung cancer. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to T...

8910 University Center Lane

Suite 700

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-550-0780

Fax:

858-550-0786

Key Executives for TRACON Pharmaceuticals, Inc.

Chief Executive Officer
Chief Financial Officer
Chief Business Officer
Vice President of Product Development
Vice President of Clinical Operations
Compensation as of Fiscal Year 2014.

TRACON Pharmaceuticals, Inc. Key Developments

TRACON Pharmaceuticals Announces Executive Appointments

TRACON Pharmaceuticals announced that Paul Walker of NEA will join the TRACON board of directors and Bruce Steel of BioMed Ventures will join as a board observer. Paul Walker is a partner in NEA's Menlo Park Office. He is a board observer of Sunesis and Interleukin Genetics. Bruce Steel is the Managing Director of BioMed Ventures. The company also announced the appointment of Patricia Bitar as Chief Financial Officer. From November 2009 until April 2014, Ms. Bitar served in roles of increasing responsibility at NuVasive, Inc. serving most recently as Vice President and Corporate Controller.

TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients with Soft Tissue Sarcoma

TRACON Pharmaceuticals announced the initiation of dosing in the Phase 2 portion of a clinical trial evaluating TRC105 in combination with Votrient(R) (pazopanib), a vascular endothelial growth factor (VEGF) inhibitor, to treat patients with soft tissue sarcoma. TRC105, an anti-endoglin antibody, is being studied in multiple clinical trials in combination with agents that inhibit angiogenesis by targeting the VEGF pathway. Dose escalation in the Phase 1 portion of the clinical trial of TRC105 in combination with Votrient has been completed and the combination was well-tolerated at the approved dose of Votrient and the recommended Phase 2 dose of TRC105. The Phase 2 portion of the trial is a multicenter, open-label, nonrandomized clinical trial of TRC105 in combination with Votrient in patients with soft tissue sarcoma. Approximately 60 patients are expected to be enrolled at approximately eight sites in the United States, including the sites that conducted the Phase 1 portion of the clinical trial: Mayo Clinic-Rochester, Mayo Clinic-Jacksonville, Duke University, Mount Sinai Hospital, Sarcoma Oncology Center-Santa Monica, and the University of Alabama-Birmingham. In the Phase 2 portion of the clinical trial, TRACON expects to correlate progression-free survival and overall response rate with endoglin expression on sarcoma tissue to assess whether direct endoglin expression on sarcoma cells may serve as a biomarker that identifies responsive sarcoma subtypes.

TRACON Pharmaceuticals Appoints William LaRue to its Board of Directors

TRACON Pharmaceuticals announced that it has appointed William LaRue to its Board of Directors effective immediately. Mr. LaRue will assume the position of chair of the audit committee. Mr. LaRue served as Senior Vice President, Chief Financial Officer and Treasurer of Cadence Pharmaceuticals from June 2006 until its acquisition by Mallinckrodt in March 2014.

Similar Private Companies By Industry

Company Name Region
Schering Berlin, Inc. United States
Adynxx, Inc United States
Franck's Pharmacy, Inc. United States
Esperance Pharmaceuticals, Inc. United States
Cantrell Drug Company, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 22, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRACON Pharmaceuticals, Inc., please visit www.traconpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.